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Endocrine paraneoplastic syndromes in lung cancer: 
a respiratory physician’s perspective
Abstract
Lung malignancy is known to be one of the leading causes of cancer-related mortality. Endocrine paraneoplastic syndromes in 
lung cancer are common. These are due to secretion of various substances and not because of direct tumour invasion or me-
tastasis. These syndromes have also been associated with lung cancer prognosis. This review describes the many endocrine 
paraneoplastic syndromes seen in lung cancer and narrates their incidence, biology, clinical features, diagnosis, and management.
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Introduction
Lung cancer is considered to be the foremost 
cause of cancer-related mortality around the 
world [1]. Mortality rate in lung cancer is signif-
icant and is considered equal to that of prostrate 
and breast cancers combined. This is mainly be-
cause most of these patients present in advanced 
stages of cancer at the time of diagnosis [2]. The 
most important risk factor for lung cancer to date 
is tobacco smoke [3]. The late diagnosis of lung 
cancer in advanced stages is mainly due to the 
lack of clinical findings. Some patients may seek 
medical advice for symptoms not directly related 
to a malignancy because of the appearance of 
paraneoplastic syndromes, which in turn may 
lead to the diagnosis of cancer in the early stage, 
with early initiation of chemotherapy [4].
Paraneoplastic syndromes (PNS) are seen in 
malignant conditions with the clinical features 
caused by either production of hormones or func-
tional peptides secreted by tumour itself. These 
should not be induced by direct infiltration and 
growth of the primary malignancy or metastases 
[5]. Improper immune cross-reaction of tumour 
cells with normal host cells can also be the rare 
cause of this syndrome [6]. Most common ma-
lignancy associated with PNS is lung cancer. 
Ten percentage of patients with lung cancer can 
have these syndromes [7]. In lung cancer, PNS 
are numerous (Table 1). Humoral hypercalcaemia 
of malignancy along with the syndrome of inap-
propriate antidiuretic hormone secretion seen re-
spectively more in squamous-cell carcinoma and 
small-cell carcinoma are two of the most common 
endocrine PNS. The size of the primary tumour or 
stage of cancer has no relation with the symptom 
severity in these syndromes. These syndromes 
are diagnosed with specific criteria (Table 2), but 
all need not be fulfilled in clinical practice [5]. 
Especially, demonstration of hormones in tumour 
biopsy tissue is not practical in many cases.
The present review aims to present the inci-
dence, tumour biology, clinical features, diagnos-
Table 1. Lung cancer-associated paraneoplastic endo-
crine syndromes
Humoral hypercalcaemia of malignancy
Syndrome of inappropriate antidiuretic hormone secretion
Ectopic Cushing’s syndrome
Carcinoid syndrome
Rare: Acromegaly, hypoglycaemia, glucagonoma syndrome,  
Zollinger–Ellison syndrome
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tic criteria, and treatment options for endocrine 
paraneoplastic syndromes in lung cancer.They 
are briefly described in Table 3.
Humoral hypercalcaemia of malignancy (HHM)
Incidence
Ten percent of all patients with advanced lung 
malignancy can have hypercalcaemia, and among 
Table 3. Four most common endocrine paraneoplastic syndromes encountered in lung cancer and their features




During course of cancer: 10%
Most common histology: 
squamous-cell carcinoma
SCLC 70% of all PNS SIADH
In SCLC 7–16%
In NSCLC < 1%
10% of Cushing’s syndrome 
are paraneoplastic




Mechanism PTHrP (most common): bind 
to PTH receptors in the bone, 
kidney and influence calci-
um, phosphorous regulation
Ectopic ADH secretion by cancer 
cells which inhibit free-water 
excretion in the distal tubule 
of the kidney
Cancer cells express POMC 
precursor gene which is 
translated into a prohormone 
later cleaved into ACTH 
Serotonin release by 
cancer cells. Can be pre-





sia, polyuria, hypertonia, 
renal failure, vomiting
1) Depends on duration 
and degree of acuity
2) Frequent falls, weight gain, 
seizures, vomiting, depression 
and rarely come
1) Carcinoid: typical cush-
ingoid features like cen-
tripetal fat distribution, 
systemic hypertension, 
proximal myopathy 
2) SCLC: less cushingoid 
features, hyperglycaemia 
common, unexpected 
weight gain due to chron-
ic water retention
1) Acute: prolonged 




2) Chronic: fibrosis of 
right heart valves, ret-
roperitoneum







serum sodium < 125 mEq/l, 
urinary sodium > 40 mmol/L, 
urine osmolality > 100 mOsm/kg
Rule out other causes of hypona-
traemia — drug-induced, excess 
fluids, low intake due to cachexia
1) Demonstration of hyper-
cortisolism by- increased 
24 UFC or salivary cortisol
2) 1 mg dexamethasone 
suppression test
3) High serum ACTH level 
with the absence of 
a pituitary tumour by CT 
or MRI brain
1) 24-hour urine 5-HIAA
2) Radiolabeled oct-
reotide
Treatment 1) Tumour excision




1) Treatment of the underlying 
tumour
2) Firstline — fluid restriction 
(< 1 L/day)
3) Demeclocycline, vaptans
1) Tumour excision 
2) Ketoconazole, octreotide 
3) Bilateral adrenalectomy 
in refractory cases
1) Surgical excision of 
tumour
2) During carcinoid crisis: 
octreotide




Conversion factors for SI: calcium values to mmol/L, multiply by 0.25; cortisol values to nmol/L, multiply by 27.588; osmolality values to mmol/kg, multiply by 1; PTH 
values to ng/L, multiply by 1; and sodium values to mmol/L, multiply by 1.
ACTH — adrenocorticotropic hormone; CT — computed tomography; HHM — humoral hypercalcaemia of malignancy; HIAA — 5-hydroxyindoleacetic acid; MRI — 
magnetic resonance imaging; NET — neuroendocrine tumour; POMC — proopiomelanocortin; PTH — parathyroid hormone; PTHrP — PTH-related protein; SIADH 
— syndrome of inappropriate antidiuretic hormone secretion
Table 2. Diagnostic criteria for paraneoplastic endocrine 
syndromes
Endocrine function abnormality with absent physiologic feedback 
regulation 
Respective endocrine lung should not have any metastasis
Worsening not explained by increasing tumour burden 
Cancer treatment improves endocrine function
Tumour biopsy sample showing evidence of either hormone sub-
stance or its production 
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these, the thirty-day mortality rate can be as high as 
50% [8, 9]. Bone metastases or altered parathyroid 
gland function are usually absent in these cases. In 
lung cancer, the incidence of hypercalcaemia is 
around 5% at baseline diagnosis and can be twice 
as this eventually (around 8–12%) during the 
disease course [5–7, 10]. Most common histology 
causing HHM is squamous-cell carcinoma, and in 
up to one-fourth of them, hypercalcaemia can be 
the presenting feature [5, 6, 10–12].
Biology and mechanism
In lung cancer patients, hypercalcaemia 
in the majority of the cases is usually caused 
by HHM [13, 14]. Four mechanisms have been 
observed in malignancy-related HHM (Table 4). 
The main and most important mechanism of ac-
tion is the parathyroid hormone-related protein 
(PTHrP) secreted from cancer cells [12, 14, 15]. 
Ectopic parathyroid hormone production is one of 
the rare mechanisms [13]. Sometimes, post-che-
motherapy, chronic G-CSF exposure can cause 
hypercalcaemia in few of them as it promotes 
osteoclastic bone resorption [16, 17].
Parathyroid hormone molecule has eighty-
four amino acids while the PTHrP molecule has 
139 to 173 amino acids. These two substances 
manifest C-terminal portions differently but have 
a similar first 13 amino acids N-terminal. PTHrP 
modifies itself into a configuration and binds to 
the PTH receptor. It can simultaneously bind to 
other PTH receptors and utilise different effects 
from PTH [18]. PTHrP binds to receptors of PTH 
in the kidney and bone. This subsequently in-
fluences the bone resorption and renal control 
of electrolytes, namely phosphate and calcium. 
PTHrP does not effect on the vitamin D3 1-alpha 
hydroxylase action unlike parathyroid hormone. 
In some animal model studies, in a squamous-cell 
carcinoma cell line, the amphiregulin-EGFR sig-
nalling system reconstitution caused HHM [19].
In patients with tumours originating from 
the lungs [8], including several other organ NETs, 
hypercalcaemia secondary to PTH secretion has 
been described [20].
Rarely, tumour cells can release interleukins 
that can activate the osteoclasts (like IL-1) which 
can be the cause of malignancy-related hypercal-
caemia [21].
Clinical features and diagnosis
In lung cancer, HHM incidence is more frequent 
in those patients with significant disease burden 
(locally advanced or metastatic disease) [21]. The 
symptom level depends on the serum calcium concen-
tration (calcium levels more than 14 mg/dL are con-
sidered severe), timing of the onset and the patient’s 
precancer neurologic and renal function [22, 23].
Moderate hypercalcaemia (serum level of 
12–14 mg/dL) may result in neuromuscular symp-
toms (proximal myopathy, fatigue), neuropsychi-
atric symptoms (anxiety, confusion), circulatory 
disturbances (polydipsia, severe dehydration 
causing acute renal failure, polyuria), and gas-
trointestinal manifestations (abdominal pain, 
constipation, and rarely pancreatitis), 
Hypercalcaemia, when severe, can cause 
cognitive impairment, confusion, and even coma. 
Cardiac conduction disturbance and hypotension 
causing death may also be seen [5, 6, 13, 22]. 
Many lung cancer patients can be emaciated 
due to cancer-related cachexia with low serum 
protein values. So, their serum calcium levels 
need correction depending on the serum albumin 
values. Patient’s calcium and albumin values esti-
mation should be always made simultaneously [6].
The diagnosis is confirmed by the following 
laboratory tests: high serum levels of ionized and 
total calcium, low to normal parathyroid hormone 
(PTH) level and high PTH-related protein (PTHrP) 
concentration [8].
Treatment
Treatment of the underlying malignancy as 
radically as possible is the most successful therapy 
strategy [6]. The goal of medical care should be 
attaining electrolyte equilibrium and restoring in-
travascular volume to prevent the immediate acute 
complications of serum hypercalcaemia. Two to 
three liters of intravenous normal 0.9% saline solu-
tion will achieve this. Fluid substitution decreases 
calcium reabsorption in the kidney by increasing 
the glomerular filtration rate [7, 22]. Medications 
causing hypercalcaemia (like calcium-containing 
antacids, supplements of calcium, vitamin D, diuret-
ics like thiazides) or that aggravating mental status 
changes should be stopped whenever possible [9]. 
In refractory persistent hypercalcaemia, treat-
ment to reduce the elevated calcium levels should 
be done as per latest guidelines (including bis-
phosphonates and possibly denosumab) [6, 23]. 
Serum calcium level starts to decrease within a day 
Table 4. Humoral hypercalcaemia of malignancy causes
Parathyroid hormone-related protein 
1.25 dihydroxy vitamin D 
Parathyroid hormone 
Granulocyte colony-stimulating factor
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and normal values of calcium can be seen within 
a week following administration of intravenous 
bisphosphonates. Bisphosphonates have an influ-
ence on serum calcium levels for up to 3 weeks [5, 
24]. In treating HHM, bisphosphonates are proven 
to be the safest and most effective agents [24]. They 
also enhance the survival of patients with bone 
metastasis [23]. The important complications of 
bisphosphonates are jaw osteonecrosis due to local 
vessel vasoconstriction and acute renal failure. 
Jaw osteonecrosis can cause severe pain locally, 
jaw swelling, tooth loss, and, rarelysoft tissue loss 
exposing the underlying bone [5, 6].
In cases of PTHrP-related hypercalcaemia, 
cinacalcet can be helpful [25].
A low calcium diet and steroids are usually 
less effective.
Dialysis is generally reserved for those with 
severe hypercalcaemia causing life-threatening 
symptoms or in patients with acute renal failure. 
Prognosis
In lung cancer, those with significant disease 
burden (locally advanced or metastatic disease) 
have more chances of having HHM with mean 
survival of only around 2 months and poor prog-
nosis [26]. 
In a study of 1,149 histologically proven 
lung cancer patients, hypercalcaemia was seen 
in 6%. Among those with hypercalcaemia, squa-
mous-cell carcinoma was found in 51%, adeno-
carcinoma in 22% and small-cell carcinoma in 
15%. Those with hypercalcaemia mostly had 
advanced disease (stage 3 or more) with a median 
survival of only a few months [11].
Serum PTHrP levels in patients with HHM 
can give information regarding prognosis. In some 
cases, it can be used to assess tumour response 
posttreatment. It may also predict the reaction 
to bisphosphonates. Studies have shown that 
concentrations above 12 pmol/L are frequently 
associated with both a smaller reduction in hyper-
calcaemia and with recurrence of hypercalcaemia 
within fourteen days of therapy [27, 28]. 
Prognosis of lung cancer-associated hyper-
calcaemia is generally poor. Those who become 
normocalcaemic after bisphosphonate therapy 
survive better (53 days vs 19 days ) [27].
Syndrome of inappropriate antidiuretic 
hormone secretion
Incidence
A syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) causing hypona-
traemia with cancer background was noticed 
in 1957 for the first time. In 1963, from a lung 
tumour sample (small-cell carcinoma), an agent 
with ADH-like action was isolated [29, 30]. This 
syndrome manifests as hyponatraemia with 
euvolemia clinically, low serum osmolality and 
unsuitably high urine osmolality. Diagnosis has 
a specific criterion (Table 4). The tumour cell 
more commonly produces antidiuretic hormone 
and rarely atrial natriuretic peptide leading to 
paraneoplastic hyponatraemia. Antidiuretic hor-
mone increases reabsorption of free water and 
atrial natriuretic peptide induces natriuresis [31].
SIADH is found in 1–2% of patients with 
lung cancer. SIADH causing clinical symptoms 
has been seen to occur in around 10% of lung 
cancer patients, mainly with small-cell carcinoma 
histology. Less than one percent of paraneoplastic 
hyponatraemia is caused by NSCLC. In SCLC, tu-
mour stage does not correlate with the incidence 
of SIADH. Overall, around 70% of paraneoplastic 
SIADH cases are caused by SCLC [32–34].
Biology/mechanism
ADH is a 9-amino acid peptide usually pro-
duced by neurohypophysis. The peptide binds to 
receptors in the kidney to reduce the excretion 
of free water. When plasma osmolality exceeds 
280 mOsm/kg, the pituitary increases ADH re-
lease, causing the kidney to retain more free water 
and maintain fluid and osmolar balance. 
In patients with SCLC, ectopic ADH produc-
tion causes hyponatraemia by inhibiting free-water 
excretion in the distal tubule of the kidney. ADH 
mRNA is expressed in SCLC cells and the peptide 
is translated and secreted. Measured levels of ADH 
in plasma are often increased in SCLC [35]. A sub-
group of hyponatraemia and concurrent SCLC cases 
have no detectable levels of plasma ADH. The tu-
mours in these patients express ANP mRNA, secrete 
the peptide, and have high plasma ANP levels [36].
Clinical findings/diagnosis
In SIADH, the level of sodium in serum and 
its time of onset determines the symptoms. Ini-
tially, the patients can have only headache and 
fatigue as presenting complaints. However, acute 
onset (< 48 hours) and severe hyponatraemia 
(serum sodium level of less than 120 meq/L) can 
cause general seizures, altered mental status and 
rarely death due to cerebral oedema. Usually, 
chronic hyponatraemia patients are asymptomat-
ic, especially when it’s mild to a moderate degree.
In the background of hyponatraemia with 
clinical euvolemia status, > 40 mmol/L of sodium 
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in urine or > 100 mOsm/kg of osmolality in urine 
gives a clue to the diagnosis of SIADH [37]. The 
diagnosis of SIADH is confirmed by laboratory 
tests as given in Table 5.
Always, in patients having hyponatraemia 
in the setting of lung cancer, other causes of low 
serum sodium like inadequate sodium intake, 
drug-induced kidney injury or excess intravenous 
hypotonic solutions usage should be excluded.
Treatment
Surgical excision of the tumour is always the 
ideal treatment and when successful, can bring 
back the serum sodium level to normal in only 
some patients [33]. In SCLC, post-chemotherapy 
symptoms resolution can be seen in up to 80% of 
cases, but the syndrome would relapse along with 
the tumour (in 60–70% of patients) [33, 34]. In 
SCLC, rarely can chemotherapy result in tumour 
lysis syndrome contributing to acute SIADH [38].
As in any SIADH case, in asymptomatic 
milder hyponatraemia patients, reduced (1 L/day) 
intake of free water is the first step. In symp-
tomatic hyponatraemia with serum sodium < 
120 mEq, intravenous administration of 3% so-
dium chloride solution with an infusion speed of 
up to 1 mL/kg/hour is necessary for the first few 
hours at least. Correction of serum sodium level 
should be gradual as acute restoration can lead 
to irreversible demyelination. 
Pharmacologic treatments can be used when 
conservative measures fail. Demeclocycline 
lowers renal response to ADH. Vasopressin re-
ceptor antagonists like conivaptan and tolvaptan 
enhance urine excretion of free water. These are 
effective in some cases.
Prognosis
SIADH per se carries an independent poor 
prognosis in malignancy [39].
In one study, SCLC patients with persistent 
hyponatraemia due to SIADH had worse survival. 
In this study, 61 patients had sodium level of less 
than 130 mEq/L and received at least two cycles 
of chemotherapy. Among these 61 subjects, com-
pared to 46 patients whose sodium normalised (to 
136mEq/L), the 15 patients in whom there was 
persistent hyponatraemia (< 136mEq/L) post-che-
motherapy had worse survival [40].
Ectopic Cushing’s syndrome (ECS)
Incidence
In 1962, for the first time, connection between 
CS and ectopic production of adrenocorticotrophic 
hormone (ACTH) was established in a patient with 
severe hyperadrenocorticism who was found to 
have SCLC [41]. In Cushing’s syndrome, in up 
to 10% of cases, the cause can be paraneoplastic 
[44]. In most of these cases, malignancy involved 
is lung NET (small-cell carcinoma or bronchial 
carcinoids) [41–44]. In non-neuroendocrine tu-
mours, rarely are ECS reported [45].
Biology and mechanism
Ectopic production of ACTH happens to be 
the foremost cause of this endocrine syndrome in 
lung cancer patients [46]. Rarely, it is caused by 
corticotropin-releasing hormone (CRH) secretion 
from tumour cells [47].
The precursor gene, proopiomelanocortin 
(POMC), is expressed more in the cancer cells 
from which a 241-amino acid prohormone is 
translated and then cleaved into ACTH (39 amino 
acids), melanocyte-stimulating hormone, and opi-
ate-like hormones. The ACTH binds to receptors 
in the adrenal gland, causing them to produce 
excessive glucocorticoid and mineralocorticoid 
hormones [48]. CRH is a 41-amino acid peptide 
produced and released in the hypothalamus para-
ventricular nuclei that stimulates the release of 
ACTH from the pituitary. 
Clinical features and diagnosis
Systemic manifestations in this syndrome are 
mainly due to increased serum cortisol levels. The 
common clinical features of ECS are skin purple 
striae, moon like face, acne, proximal myopathy, 
oedema of the periphery, systemic hypertension, 
primary metabolic alkalosis, and persistent serum 
hypokalaemia. Weight gain (due to chronic water 
retention or centripetal fat distribution) may be one 
of the rare features in those with lung cancer-relat-
ed ECS unlike in those without ECS where weight 
loss is seen because of cachexia [7]. Most of them 
also have hyperglycaemia [48, 49]. In ECS, due to 
SCLC, classical signs of Cushing’s syndrome are 
rare. An important reason for this finding could be 
the aggressive nature of SCLC causing only brief 
exposure to excessive ACTH [5, 50].
Table 5. Syndrome of inappropriate antidiuretic hormone 
secretion diagnosis criteria
Serum sodium level of less than 134 mEq/L
Osmolality of plasma less than 275 mOsm/kg 
Osmolality of urine more than 500 mOsm/kg 
Concentration in urine more than 20 mEq/L 
All should be absent: hypovolaemia, adrenal insufficiency, 
and hypothyroidism
Advances in Respiratory Medicine 2021, vol. 89, no. 4, pages 403–412
408 www.journals.viamedica.pl
Those having SCLC with ECS getting che-
motherapy are at increased risk for opportunistic 
infections [51]. ECS is also a risk factor for VTE 
(2%) [52]. This risk further may increase after 
surgery of the tumour (4%) [53].
Diagnostic laboratory findings include the 
following [54]: 
1. Minimum of 2 increased measurements of 
24-h urine free cortisol;
2. Salivary cortisol sample > 145 ng/dL between 
23:00–24:00;
3. 1 mg of dexamethasone suppression test.
An ACTH level can differentiate ECS from 
Cushing’s in cases of proven serum or urine hy-
percortisolism. ECS suspicion is raised when an 
elevated morning ACTH is seen along with the 
absent pituitary tumour in brain CT or MRI. High-
dose dexamethasone will not suppress an ectopic 
source (like in lung cancer) of ACTH. Bronchial 
carcinoids are an exception, because in some 
cases with this tumour type, serum ACTH and 
cortisol levels have been suppressed by high-dose 
dexamethasone [55].
To locate the primary tumour in the lungs, 
whole body somatostatin receptor scintigraphy 
or thorax imaging like CT can be used.
Treatment
Radical excision of the tumour is the best 
treatment [56]. When radical therapy of the 
tumour is unattainable, medications directed 
to cease the secretion of cortisol (ketoconazole, 
metyrapone and other drugs) or block (octreotide 
may block the release of ACTH) are required [7, 
57]. With careful monitoring of serum potassium, 
antihypertensive agents and diuretics can also be 
used to control symptoms.
Bilateral adrenalectomy is the option used 
as a last resort in case of no response to medi-
cations [5].
Prognosis
Prognosis is affected by tumour type and 
degree of cortisol level as both these factors in-
fluence mortality and morbidity [56].
Most of the patients with SCLC and ECS pres-
ent at an advanced stage. Even with chemothera-
py, their mortality is significantly high since many 
of these tumours are chemoresistant [5, 7, 56]. 
Carcinoid syndrome
Incidence
Neuroendocrine tumours of the bronchopul-
monary system account for around 20% of all lung 
malignancies and include typical carcinoid, atypi-
cal carcinoid, large-call carcinoma and SCLC [58]. 
In neuroendocrine lung cancer, the release 
of serotonin by tumour cells might trigger the 
syndrome only in 1–5% of the cases [59]. A lower 
rate of carcinoid syndrome is seen in lung NET 
as they produce less serotonin than midgut NET 
[58]. In patients having localised disease (like in 
most of the cases of lung NET), carcinoid syn-
drome is seen most often with tumours of bigger 
size (> 5 cm) and those with concurrent liver 
metastasis [60]. 
Biology and mechanism
Carcinoid syndrome results from the release 
of vasoactive substances such as serotonin into 
the systemic circulation. As many as 40 sub-
stances (dopamine and many others) related to 
carcinoid syndrome have been identified as being 
the potential causes. The release of these sub-
stances can be triggered by increased adrenergic 
activities, such as physical exercise, or increased 
intake of foods rich in amines (chocolate, kiwi, 
avocado banana, and nuts) or alcohol.
Clinical features and diagnosis
Some may have acute symptoms like cuta-
neous flushing, secretory diarrhoea, and bron-
chospasm. The long-term results of persistently 
elevated hormone levels include telangiectasias 
of veins, valvular heart disease (right side more 
commonly involved), and retroperitoneum fibro-
sis. Flushing of the skin can be prolonged in the 
setting of carcinoid syndrome due to lung NET 
and it occurs more in the upper anterior part of 
the body [61, 62].
Carcinoid syndrome-associated broncho-
spasm is less typical and these patients usually 
have concurrent flushing, sneezing and dyspnoea 
[63]. In a retrospective study of 748 carcinoid 
syndrome patients, bronchospasm was seen in 
15% [63]. 
In few cases, due to excessive production 
of serotonin and its release into the systemic 
circulation, an acute form of the syndrome can 
be seen. This is known as carcinoid crisis. These 
patients can have tachycardia, hypotension, 
bronchospasm, and even rarely sudden death. 
Carcinoid crisis is more common after stressful 
procedures such as anaesthesia, surgery or even 
radiologic interventions [64]. It can also happen 
spontaneously.
The evaluation of carcinoid syndrome is with 
a 24-hour urine collection for the most crucial 
metabolite of serotonin, 5-Hydroxyindoleacetic 
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acid (5-HIAA). This test has a specificity of ap-
proximately 90% [65].
Radiolabelled octreotide can be used to de-
tect lung neuroendocrine tumours with ectopic 
hormone production as almost 80% of them 
demonstrate somatostatin receptors [66]. 
Treatment
Excision of the tumour is the best treatment 
[67]. Unlike other organ NETs (even with signif-
icant liver metastasis), carcinoid crisis risk with 
lung NETs is low, and hence prophylactic admin-
istration of octreotide before any tumour manip-
ulation (biopsy or resection) is not recommended 
[62]. But still, when handling such tumours, 
clinicians should be aware of the possibility of 
the carcinoid crisis and the benefit of octreotide 
in such a scenario.
Rare syndromes
Hypoglycaemia
Lung cancer-associated paraneoplastic hypo-
glycaemia is rare. Non-isletcell tumours with in-
sulin secretion and tumours releasing substances 
which can cause hypoglycaemia by non-insulin 
based mechanism are the main causes [68]. This 
condition is labelled as non-islet cell tumour hy-
poglycaemia (NICTH). Pulmonary tumours caus-
ing this condition are malignant mesothelioma, 
solitary fibrous tumour and adenocarcinomas [6].
In most of the cases, hypoglycaemia is caused 
by excess insulin release due to the secretion of 
peptides like precursors of insulin-like growth 
factor 2 (IGF-2), insulin-like growth factor 1, and 
sometimes glucagon-like peptide-1 which are 
capable of causing glucose utilisation by different 
mechanisms [68]. Rarely high tumour load having 
excess glucose utilisation, significant liver infil-
tration by tumour per se, or tumour metastasis to 
the endocrine gland (pituitary or adrenal) causing 
their destruction is the cause of hypoglycaemia 
in these patients [68].
NICTH is clinically characterised by recur-
rent hypoglycaemic episodes which affect elderly 
patients more often. In some, these hypoglycae-
mic episodes may direct towards the underlying 
undiagnosed cancer [69, 70]. 
Diagnosis depends on tumour type the pa-
tient is having. In NICTH acute phase, we can 
find decreased values of following substances 
in serum-insulin (normal range: 1.44–3.6 μIU/ 
mL) and C-peptide (normal range: 0.3 ng/mL). 
They would also have increased levels of the 
following substances in serum: growth hormone, 
insulin-like growth factor 1, insulin-like growth 
factor 2 and IGF2:IGF1 ratio. In insulinoma acute 
phase, we can find increased value of both insulin 
and C-peptide levels in serum [6, 70]. 
Surgery of the tumour is the best manage-
ment option in these patients. The essential goal 
in case of any hypoglycaemic emergencies is to 
bring back blood glucose to near expected val-
ues with 25% or 50% solution of dextrose. Oral 
glucose will help in few cases. In the long run, 
treatment of hypoglycaemia due to this syndrome 
may require glucagon, growth hormone and cor-
ticosteroids [6, 69–71].
Acromegaly
Only 1% of acromegaly is caused by growth 
hormone releasing hormone or growth hormone 
ectopic secretion by tumour cells. Of these, the 
majority are caused by carcinoid tumours of the 
lung and intestine [72]. In most cases, the GHRH 
gene is expressed by the lung cancer cells, and 
a 40–44 amino acid peptide is produced. Circu-
lating GHRH peptide binds to receptors in the 
pituitary gland resulting in the production of 
excessive amounts of GH 73]. Rarely, lung carci-
noid tumours express immunoreactive GHRH and 
result in abnormal GH secretion [74]. 
The earliest features of GH excess are hyper-
trophy of the extremities and face. The diagnosis 
of ectopic acromegaly is established by elevated 
serum levels of GHRH or GH, the absence of 
a pituitary tumour, complete recovery following 
lung tumour resection, positive GHRH immu-
nostaining, detection of GHRH mRNA, positive 
bioassay (pituitary cells of rat on culture produce 
GH when subjected to tumour extract), or GHRH 
extraction from the tumour tissue [75]. However, 
coincidental pituitary tumours and lung solid 
tumours have also been described. 
Management of ectopic acromegaly should 
be surgical resection of the tumour and is often 
curative in those with lung carcinoid. In those 
with unresectable or metastatic cancers, medical 
therapy with somatostatin analogues, such as 
octreotide and bromocriptine, have been shown 
to be effective [76].
Ectopic secretion of chorionic 
gonadotropin
This syndrome has been reported in large-cell 
lung carcinoma (LCLC). The syndrome causes 
Leydig cell hyperplasia which results in raised oes-
trogen levels and reduced testosterone production. 
This gives rise to atrophy of testicles with repres-
sion of spermatogenesis, and gynecomastia [77].
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Conclusion
Despite the availability of new diagnostic 
techniques and biological and surgical treatment 
development, lung malignancy mortality is the 
foremost cause of cancer-related deaths since 
1985.
In lung cancer, the small-cell histology type 
is commonly associated with endocrine parane-
oplastic syndromes. These syndromes are easy 
to diagnose and treat because they have a clear 
pathogenic pathway. Endocrine paraneoplastic 
syndromes have both a prognostic role as well 
as a predictive function in tumour treatment 
success. The prognosis also depends on the cure 
of the underlying tumour. Tumour progression 
can present along with syndrome recurrence. 
The most common syndrome is humoral hyper-
calcaemia of malignancy seen in squamous-cell 
histology and measurement of PTHrP can delin-
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